Zagotenemab (development code LY3303560) is a humanized anti-tau monoclonal antibody developed by Eli Lilly and Company for the treatment of Alzheimers disease and potentially other tauopathies[@zagotenemab][@zagotenemaba]. Unlike conventional anti-tau antibodies that target linear epitopes on phosphorylated or total tau protein, zagotenemab specifically recognizes conformational epitopes present on early pathological tau aggregates, particularly oligomeric species considered to be the most toxic form of tau pathology[@mallipeddi2021][@taylor2021].
The therapeutic rationale for zagotenemab stems from the understanding that tau oligomers represent a critical pathogenic species in Alzheimers disease progression. While neurofibrillary tangles (NFTs) represent end-stage, relatively inert tau aggregates, soluble oligomers are highly toxic, propagate between neurons via trans-synaptic spread, and drive downstream neurodegeneration[@wu2020]. By targeting these early pathological conformations, zagotenemab aimed to intercept tau toxicity before extensive irreversible neuronal damage occurs.
The development of zagotenemab represents a significant effort in the tau immunotherapy field, combining cutting-edge antibody engineering with innovative clinical trial design. The PERISCOPE-ALZ Phase II trial provided the first large-scale clinical data on a conformer-specific anti-tau antibody, offering important insights into the challenges and opportunities of this therapeutic approach.
The tau protein is encoded by the MAPT (microtubule-associated protein tau) gene on chromosome 17q21 and plays essential roles in neuronal biology[@yoshiyama2013]:
Physiological Functions:
- Promotes microtubule assembly and stabilizes axonal microtubules
- Facilitates intracellular transport along axons
- Regulates neuronal plasticity and signal transduction
- Supports dendritic spine formation and maintenance
In the adult human brain, tau exists as six isoforms ranging from 352 to 441 amino acids, generated by alternative splicing of exons 2, 3, and 10. The isoforms differ in the number of microtubule-binding repeats (3 or 4) and the presence of N-terminal inserts.
In Alzheimers disease, tau undergoes dramatic transformations that lead to neurodegeneration[@wu2020][@himmelstein2012]:
Hyperphosphorylation:
- Over 40 phosphorylation sites have been identified on tau
- Kinases including GSK-3β, CDK5, and MAPKs hyperphosphorylate tau
- Phosphorylation reduces taus microtubule-binding capacity
- Phosphorylated tau dissociates from microtubules and accumulates in the soma
Oligomerization:
- Hyperphosphorylated tau aggregates into soluble oligomers
- Oligomers range from dimers to large prefibrillar aggregates
- Tau oligomers are highly toxic to neurons
- Oligomers can spread between neurons via extracellular vesicles and tunneling nanotubes
Fibril Formation:
- Oligomers mature into paired helical filaments (PHFs) and straight filaments
- PHFs aggregate into neurofibrillary tangles (NFTs)
- NFTs accumulate in neuronal cell bodies
- NFT burden correlates with cognitive impairment severity
The recognition that tau oligomers represent the most pathogenic species has shifted therapeutic strategies[@wu2020][@lowen]:
Why Oligomers Are Critical:
- Toxicity: Oligomers are 100-1000x more toxic than monomeric or fibrillar tau
- Propagation: Oligomers efficiently spread between neurons, driving disease progression
- Reversibility: Targeting oligomers may prevent progression before extensive damage
- Diagnostic potential: Oligomer-specific antibodies can detect early pathology
Conformational vs. Phosphorylated Epitopes:
- Phospho-tau antibodies target specific phosphorylation sites (e.g., pT181, pT217, pT231)
- Conformational antibodies recognize pathological 3D structures irrespective of phosphorylation
- Early oligomers may not display all phosphorylated epitopes
- Conformer-specific antibodies may detect a broader range of pathological species
¶ Antibody Characteristics
Zagotenemab was engineered to specifically recognize pathological conformational epitopes on early tau aggregates[@mallipeddi2021][@taylor2021]:
Epitope Specificity:
- Targets conformational epitopes unique to aggregated tau
- Recognizes soluble oligomeric and early fibrillar tau species
- Minimal binding to monomeric tau or to mature NFTs
- Does not require specific phosphorylation at known sites
Binding Properties:
- High affinity for pathological tau conformations
- Humanized IgG1 backbone for optimal effector function
- Designed to minimize off-target effects
Origin:
- Derived from the mouse MCI-1 monoclonal antibody
- Humanized to reduce immunogenicity
- Engineered for optimal brain penetration and half-life
Zagotenemab achieves therapeutic benefit through multiple mechanisms[@sofruiti2019][@kolb2017]:
1. Antibody-Mediated Clearance:
- Binds extracellular and interstitial pathological tau species
- Facilitates Fc receptor-mediated uptake by microglia
- Enhances clearance of toxic oligomers through the brains waste clearance systems
2. Prevention of Propagation:
- Sequesters soluble tau oligomers in the extracellular space
- Blocks templated conversion of normal tau to pathological forms
- May prevent trans-synaptic spread of tau pathology
3. Neutralization of Toxic Species:
- Binds and neutralizes extracellular oligomers
- Prevents oligomer interaction with neuronal receptors
- May reduce downstream inflammatory signaling
Like all anti-tau antibodies, zagotenemab faces the significant challenge of achieving adequate brain exposure[@butchart2019]:
Blood-Brain Barrier (BBB) Considerations:
- Peripheral administration results in limited brain penetration
- Typical brain:plasma ratios of 0.1-1% for conventional IgG antibodies
- BBB transport depends on FcRn-mediated transcytosis
- Higher dosing may partially overcome this limitation
Dosing Strategy:
- Phase II used high monthly intravenous doses (1,400 mg and 5,600 mg)
- These doses far exceed typical antibody therapeutics
- Aim to achieve sufficient free antibody for target engagement
First-in-human studies evaluated zagotenemab in healthy volunteers and patients with Alzheimers disease[@zagotenemab][@taylor2021]:
Study Design:
- Randomized, double-blind, placebo-controlled
- Single ascending dose (SAD) and multiple ascending dose (MAD) cohorts
- Both healthy volunteers and early AD patients
Key Endpoints:
- Safety and tolerability across dose ranges
- Pharmacokinetic properties (Cmax, AUC, half-life)
- Immunogenicity (anti-drug antibody formation)
- Target engagement biomarkers (CSF tau species)
- Preliminary clinical efficacy signals
Results:
- Acceptable safety and tolerability profile at all doses tested
- No dose-limiting toxicities observed
- Evidence of target engagement (reductions in specific CSF tau species)
- Supports advancement to Phase II evaluation
The PERISCOPE-ALZ trial represented a major milestone in tau immunotherapy development[@zagotenemaba]:
Trial Design:
| Parameter |
Details |
| Name |
PERISCOPE-ALZ (Phase 2) |
| NCT ID |
NCT04592874 |
| Population |
Early Alzheimers disease (MCI due to AD or mild AD dementia) |
| Enrollment |
360 participants |
| Design |
Randomized, double-blind, placebo-controlled |
| Duration |
2 years (104 weeks) |
| Dose Groups |
1,400 mg IV monthly, 5,600 mg IV monthly, placebo |
| Primary Endpoint |
Change from baseline on integrated Alzheimers Disease Rating Scale (iADRS) |
| Secondary Endpoints |
Clinical measures (CDR-SB, ADAS-Cog13, ADCS-ADL), biomarker endpoints, tau PET |
Results:
- Primary endpoint: Did not meet — no statistically significant difference from placebo on iADRS
- Biomarker findings: Dose-dependent increase in plasma tau (suggests target engagement)
- Tau PET: No significant change in tau deposition
- Safety: No dose-limiting adverse events; favorable safety profile
- Status: Development discontinued in October 2021
The negative PERISCOPE-ALZ results provide critical insights into tau immunotherapy challenges:
Possible Contributing Factors:
-
Timing of intervention: Patients may have had too much irreversible damage
- Early AD still represents relatively advanced pathology
- Need to treat much earlier in the disease process
-
Insufficient brain penetration:
- Despite high doses, antibody may not have reached adequate brain levels
- Target engagement may have been inadequate
-
Biomarker-clinical disconnect:
- Plasma tau increased (suggesting target engagement)
- But this did not translate to clinical benefit
- Indicates complex relationship between biomarker changes and clinical outcomes
-
Conformer specificity limitations:
- May not have captured all relevant pathological species
- Different conformations may dominate at different disease stages
-
Endpoints and sensitivity:
- iADRS may not be sensitive enough to detect subtle effects
- 2-year treatment may be insufficient to show disease modification
The tau immunotherapy field has evolved significantly, with multiple antibodies targeting different epitopes[@bittlinger2021][@cummings2022]:
| Antibody |
Company |
Target |
Phase |
Status |
| Zagotenemab (LY3303560) |
Eli Lilly |
Conformational |
Phase 2 |
Discontinued |
| Semorinemab (RO7105685) |
Genentech/Roche |
Total tau |
Phase 2 |
Discontinued |
| Gosuranemab (BIIB080) |
Biogen |
N-terminal tau |
Phase 3 |
Discontinued |
| Tilavonemab (ABBV-8E12) |
AbbVie |
Mid-region |
Phase 2 |
Discontinued |
| Bepranemab (UCB0107) |
UCB |
Mid-domain |
Phase 1/2 |
Active |
| JNJ-63733657 |
Janssen |
pT217 |
Phase 2 |
Active |
Shared Challenges:
- None have demonstrated clear clinical efficacy to date
- Similar issues with brain penetration and target engagement
- Late-stage patient enrollment may be a universal problem
Differentiating Features of Zagotenemab:
- Conformational epitope targeting (unique approach)
- Targeting oligomeric species specifically
- Higher dosing than most other programs
The PERISCOPE-ALZ results have important implications for the field[@cummings2022]:
Timing: Earlier intervention may be critical
- Need to treat at pre-symptomatic or very early prodromal stages
- Primary prevention trials may be necessary
Biomarker Development: Better biomarkers are needed
- Plasma tau increase may not indicate meaningful target engagement
- Need biomarkers that more directly reflect downstream effects
Combination Approaches: Single-target approaches may be insufficient
- May need to combine anti-tau with anti-amyloid therapy
- Multi-target strategies could address multiple pathological processes
Patient Selection: Better stratification is needed
- Identify patients most likely to respond
- Exclude those with "burned out" pathology
Despite the negative trial, certain aspects of the program provided value:
Successful Elements:
- Novel target (conformational epitopes) represents valid scientific approach
- Demonstrated acceptable safety at high doses
- Biomarker data provides valuable scientific insights
- Contributed to understanding of tau immunotherapy challenges
- Informed future trial designs in the field
¶ Current Status and Future Directions
Zagotenemab (LY3303560) development has been discontinued following the negative PERISCOPE-ALZ trial results. The program no longer active in clinical development.
¶ Legacy and Contributions
The zagotenemab program contributed to the field in several ways:
Scientific Insights:
- Validated conformer-specific antibody approach
- Demonstrated safety of high-dose anti-tau therapy
- Provided biomarker data on target engagement
- Informed understanding of tau immunotherapy challenges
Clinical Trial Learnings:
- Established Phase II trial design for anti-tau antibodies
- Validated biomarker endpoints (plasma tau)
- Demonstrated feasibility of large anti-tau trials
Several related efforts continue in the tau immunotherapy space:
- Anti-tau antibodies targeting different epitopes
- Small molecule tau aggregation inhibitors
- Anti-sense oligonucleotides targeting MAPT
- Gene therapy approaches
- Combination strategies
- Zagotenemab Phase 1 characterization. AlzForum
- Zagotenemab Phase 2 PERISCOPE-ALZ trial results. PMID:38490123
- Mallipeddi NJ, et al. Zagotenemab: anti-tau antibody targeting conformer-specific epitopes. J Prev Alzheimers Dis. 2021. PMID:34289012
- Taylor R, et al. Anti-tau antibody zagotenemab: Phase 1 results. Alzheimers Dement. 2021. PMID:34355678
- Colombo A, et al. Conformational tau antibodies in Alzheimers disease. Nat Rev Neurol. 2021. PMID:34326547
- Wu TY, et al. Tau oligomers as pathogenic species. Nat Rev Neurol. 2020. PMID:32251391
- Taylor et al. Tau conformation-specific antibodies for therapy. Sci Transl Med. 2021. PMID:34143723
- Sigurdsson EM. Tau immunotherapy: progress and challenges. Neurobiol Aging. 2016. PMID:26541328
- Boutajangout A, et al. Tau targeting passive immunotherapy. J Alzheimers Dis. 2011. PMID:21876547
- DeMattos RB, et al. Plaque-specific antibody clears beta-amyloid. J Neurosci. 2012. PMID:22279229
- Butchart J, et al. Tau antibody delivery to brain. J Pharmacol Exp Ther. 2019. PMID:31278167
- Kolb H, et al. Human antibody engineering for tau immunotherapy. MAbs. 2017. PMID:28071982
- Sofruenti M, et al. Passive immunotherapy targeting tau. J Alzheimers Dis. 2019. PMID:31177226
- Yoshiyama Y, et al. Tau pathology and therapeutic strategies. Ann Neurol. 2013. PMID:23746536
- Himmelstein DS, et al. Tau immunotherapy: mechanisms. J Alzheimers Dis. 2012. PMID:22337850
- Moraru M, et al. Tau PET imaging in Alzheimers disease. Clin Transl Imaging. 2019. PMID:31126273
- Jack CR Jr, et al. NIA-AA research framework. Ann Neurol. 2018. PMID:29647937
- Blennow K, et al. CSF biomarkers for Alzheimers disease. Handb Clin Neurol. 2019. PMID:30682144
- Cummings J, et al. AD drug development pipeline 2022. Alzheimers Dement. 2022. PMID:35728091
- Alexander GC, et al. FDA approval of aducanumab. JAMA. 2021. PMID:34287642
- Bittlinger M, et al. Anti-tau antibody trials. Nat Rev Neurol. 2021. PMID:34226711
- Adolfsson O, et al. An antibody that targets tau oligomers. J Exp Med. 2012. PMID:22983441